<DOC>
	<DOCNO>NCT00868608</DOCNO>
	<brief_summary>The purpose study evaluate efficacy inotuzumab ozogamicin ( CMC-544 ) subject indolent Non-Hodgkins lymphoma ( NHL ) refractory relapse multiple therapy include rituximab radioimmunotherapy . The investigational drug give subject indolent NHL intravenous infusion dose 1.8 mg/m2 , every 4 week .</brief_summary>
	<brief_title>Study Evaluating Inotuzumab Ozogamicin ( CMC-544 ) In Indolent Non-Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Subjects previously diagnose CD22positive , indolent NHL ( define follicular , marginal zone , small lymphocytic lymphoma ) progress 2 prior systemic therapy . Previous anticancer treatment give must contain rituximab chemotherapy , anti CD20 Radio Immuno Therapy . Subjects must exhibit response progress within 6 month completion recent rituximab rituximab contain therapy within 12 month completion Radio Immuno Therapy . Measurable disease adequate bone marrow function , renal hepatic function History , suggestive , venoocclusive disease ( VOD ) sinusoidal obstruction syndrome ( SOS ) history chronic liver disease ( eg , cirrhosis ) suspect alcohol abuse . Prior allogeneic hematopoietic stem cell transplant ( HSCT ) . Clinical evidence transformation aggressive subtype lymphoma grade 3b follicular lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Refractory Indolent NHL</keyword>
	<keyword>lymphoma</keyword>
</DOC>